Results of BAA ART LIFE HEPAR FORMULA in the treatment of neonatal jaundice.
OV Petukhova, GA YANGAEVA, IFL number 2, Tomsk
Jaundice - clinical and laboratory syndrome that accompanies many liver diseases of different etiologies. Sometimes with jaundice occur some blood diseases. Develops the syndrome as a result of violations of bilirubin metabolism in the body. In the neonatal period there are several features of bilirubin metabolism.
The first children's department of MSU ¹ 2 during the year used biologically active food supplement HEPAR FORMULA produced by ART LIFE . During this period in the department have treated 68 children with prolonged neonatal jaundice, with 18 of them were diagnosed with intrauterine infection with liver disease, one patient found rarely found genetically determined abnormality - galactosemia.
All the children in the department received the following therapies: intravenous drip - glucose, insulin, vitamin C, 5%, but, MSE essentiale. In addition, 48 patients (70,5%), the first group received HEPAR FORMULA, which includes:
- Milk thistle, which has the ability to stabilize cell membranes;
- Turmeric, which improves the life processes of liver cells;
- Thistle curly, bactericidal, antiviral, anti-inflammatory action;
- A set of phospholipids: lecithin, choline, inositol, improves the functional state of cell membranes;
- Methionine - an amino acid normalizes metabolism of choline;
- Vitamin B6 (pyridoxine), which improves a variety of enzymatic reactions;
Twenty patients, constituting the second group received no HEPAR FORMULA. They took an activated carbon, no-silos allohol, broth hips. Patients of the first group took HEPAR FORMULA early in the course of treatment for 1 / 4 tablet 2 times a day after two weeks of use - 1 / 2 tablets 2 times a day rate of up to 1 month. Established that these patients length of stay in hospital was only 6 days, icteric staining of the skin has changed for 2-4 days, the level of bilirubin in the blood dropped to normal earlier than did patients of the second group. Thus, given the foregoing, it can be concluded that HEPAR formula can be recommended for the treatment of liver diseases in children and adults and, in particular for the treatment of neonatal jaundice, as it possesses good hepatoprotective properties.
